The compound you're referring to, **1-(2-chloroethyl)-1-nitrosocarbamoylalanine estradiol-17-ester**, is not a commonly known or studied compound. It's likely a synthetic derivative or an experimental compound, not a naturally occurring one.
Here's why:
* **The name itself is complex:** The structure is built from several distinct components:
* **1-(2-chloroethyl)-1-nitrosocarbamoylalanine**: This is a modified amino acid with a chloroethyl and a nitrosocarbamoyl group. These groups are typically used for their chemical reactivity and potential for biological activity.
* **estradiol-17-ester**: This is a derivative of the female sex hormone estradiol, with an ester group attached at the 17th position. Esters are commonly used to modify the properties of drugs, including their absorption, distribution, and metabolism.
* **Lack of established research:** There is no readily available information about this compound in scientific databases or published research.
**Why it might be important for research:**
Given the components of this compound, it's likely that researchers might be interested in it for the following reasons:
* **Investigating new hormonal therapies:** The presence of estradiol suggests that this compound could potentially interact with the estrogen receptor system, potentially leading to new hormone-based treatments for various conditions.
* **Developing new anticancer agents:** The presence of the chloroethyl group, often found in alkylating agents, might suggest potential anticancer activity.
* **Studying the effects of specific chemical modifications:** Researchers could be interested in understanding the effects of the nitrosocarbamoylalanine modification on the activity and properties of estradiol.
**Important Note:** Without further information about the context of this compound and its specific research goals, it's impossible to definitively assess its importance.
**To learn more about this compound:**
1. **Check specialized databases:** Search chemical databases like PubChem, ChemSpider, or Reaxys for the specific name or its components.
2. **Look for specific publications:** Search for publications that mention the compound's name or its chemical structure.
3. **Contact experts:** Contact researchers in related fields (e.g., medicinal chemistry, hormone research) to see if they have information about this compound.
1-(2-chloroethyl)-1-nitrosocarbamoylalanine estradiol-17-ester: RN refers to (L-Ala)-(17-beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 67377 |
| MeSH ID | M0158097 |
| Synonym |
|---|
| 1-(2-chloroethyl)-1-nitrosocarbamoylalanine estradiol-17-ester |
| l-alanine, n-(((2-chloroethyl)nitrosoamino)carbonyl)-, (17-beta)-3-hydroxyestra-1,3,5(10)-trien-17-yl ester |
| 2-chloroethylnitrosocarbamoyl-l-alanine 17-oestradiol ester |
| n-(2-chloroethyl)-n-nitrosocarbamoyl-l-alanine-estradiol-17-ester |
| (3-hydroxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl) 2-[[2-chloroethyl(nitroso)carbamoyl]amino]propanoate |
| 3-hydroxyestra-1,3,5(10)-trien-17-yl n-[(2-chloroethyl)(nitroso)carbamoyl]alaninate |
| 93398-55-1 |
| DTXSID80275698 |
| 105802-02-6 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " However, there is only little knowledge about the pharmacokinetic behavior of this new group of anticancer agents." | ( A new comprehensive technique of catheterisation, blood sampling, sample preparation and sample analysis by means of high-pressure liquid chromatography for pharmacokinetic studies with estradiol-linked nitrosoureas and their metabolites. Berger, MR; Betsch, B; Spiegelhalder, B, 1990) | 0.28 |
| " The higher antineoplastic activity of the hormone-linked drug can mainly be attributed to differences in the pharmacokinetic behaviour." | ( New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities? Berger, MR; Betsch, B; Eisenbrand, G; Schmähl, D; Spiegelhalder, B, 1989) | 0.28 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of the estradiol-linked drug was determined to be 52%." | ( New estradiol-linked nitrosoureas: can the pharmacokinetic properties help to explain the pharmacodynamic activities? Berger, MR; Betsch, B; Eisenbrand, G; Schmähl, D; Spiegelhalder, B, 1989) | 0.28 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (62.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.18) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||